3 imperatives to transform health care in America. You're invited to watch it live

Free

E-newsletter

Subscribe to Housecall

Our weekly general interest
e-newsletter keeps you up to date on a wide variety of health topics.

Sign up now

Causes

By Mayo Clinic staff

Vaginal atrophy is caused by a decrease in estrogen production. Less circulating estrogen makes your vaginal tissues thinner, drier, less elastic and more fragile.

A drop in estrogen levels and vaginal atrophy may occur:

  • After menopause
  • During the years leading up to menopause (perimenopause)
  • During breast-feeding
  • After surgical removal of both ovaries (surgical menopause)
  • After pelvic radiation therapy for cancer
  • After chemotherapy for cancer
  • As a side effect of breast cancer hormonal treatment

Vaginal atrophy due to menopause may begin to bother you during the years leading up to menopause (perimenopause), or it may not become a problem until several years into menopause. Although the condition is common, not all menopausal women develop vaginal atrophy. Regular sexual activity helps you maintain healthy vaginal tissues.

References
  1. Bachmann G, et al. Diagnosis and treatment of vaginal atrophy. http://www.uptodate.com/patients/index.html. Accessed Aug. 6, 2010.
  2. The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. 2007;14:357.
  3. MacBride MB, et al. Vulvovaginal atrophy. Mayo Clinic Proceedings. 2010;85:87.
  4. Palacios S. Managing urogenital atrophy. Maturitas. 2009;63:315.
  5. Suckling JA, et al. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews. 2006:CD001500.
  6. Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause. 2010;17:194.
  7. Reed SD, et al. Vaginal, endometrial, and reproductive hormone findings: Randomized, placebo-controlled trial of black cohosh, multibotanical herbs and dietary soy for vasomotor symptoms: The Herbal Alternatives for Menopause (HALT) study. Menopause. 2008;15:51.
  8. Mehta A, et al. Vulvovaginal complaints. Clinical Obstetrics and Gynecology. 2008;51:549.
  9. Labrie F, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause. 2009;16:907.
  10. Panjari M, et al. DHEA for postmenopausal women: A review of the evidence. Maturitas. 2010;66:172.
DS00770 Sept. 17, 2010

© 1998-2013 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.com," "EmbodyHealth," "Enhance your life," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.

  • Reprints
  • Print
  • Share on:

  • Email

Advertisement


Text Size: smaller largerlarger